| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SLF TFA primarily targets FK506-binding proteins, specifically FKBP12 and FKBP51. FKBP12 is a cytosolic prolyl isomerase that has been frequently used to study ligand-induced protein degradation. The compound exhibits an affinity of 3.1 microM for FKBP51 and an IC50 of 2.6 microM for FKBP12.
|
|---|---|
| ln Vitro |
Three segments (KB02, KB03, and KB05) show significant cysteine coverage with SLF ligands in the human proteome, when fused together, covering two distinct electrophilic groups (acrylamide and chloroacetamide). This ligand is reactive and specifically binds to FKBP12, a cytosolic prolyl isomerase that is widely employed in research on the degradation of proteins induced by ligands [3].
In vitro, SLF TFA demonstrates high-affinity binding to FKBP12, a cytosolic prolyl isomerase. Three scout fragments (KB02, KB03, and KB05) fused to the SLF ligand display broad cysteine reactivity in the human proteome. The compound is reactive and specifically binds to FKBP12, making it a valuable tool for studying ligand-induced protein degradation. |
| ln Vivo |
In vivo activity data for SLF TFA are limited as it is primarily used as a chemical tool for in vitro PROTAC development rather than a therapeutic agent. Its in vivo effects are typically dependent on the specific PROTAC molecule in which it is incorporated. The compound's utility lies in its ability to recruit FKBP proteins for targeted degradation studies in cellular and potentially in vivo models.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for SLF TFA typically involves competitive binding assays using purified FKBP12 or FKBP51 proteins. Radiolabeled or fluorescence-labeled FK506 analogs are used as tracers. The compound is incubated with the target protein and tracer, and binding affinity is determined by measuring displacement of the tracer. IC50 values are calculated from dose-response curves. Assays are performed in buffer systems at physiological pH.
|
| Cell Assay |
In vitro cell-based assays for SLF TFA typically involve treating cultured cells with SLF TFA-containing PROTAC molecules to assess targeted protein degradation. Cells are incubated with the compound for varying time points (e.g., 4-24 hours), followed by western blot analysis to measure target protein levels. Cellular viability and proliferation can be assessed using MTT or CCK-8 assays. Degradation efficiency is quantified by densitometry analysis of protein bands.
|
| Animal Protocol |
In vivo animal studies using SLF TFA are typically conducted in the context of specific PROTAC molecules rather than SLF TFA alone. Standard protocols involve administration of the PROTAC compound via intravenous, intraperitoneal, or oral routes in rodent models. Tissue samples are collected at various time points for pharmacokinetic analysis and target protein degradation assessment by immunohistochemistry or western blot. Tumor xenograft models may be used for efficacy evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of SLF TFA are primarily characterized in the context of PROTAC molecules. The compound has high DMSO solubility (200 mg/mL, approximately 313 mM). The TFA salt form enhances solubility compared to the free base. As a small molecule ligand, it is expected to have favorable cell permeability. Detailed PK parameters such as half-life, clearance, and bioavailability are dependent on the specific PROTAC conjugate formulation.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for SLF TFA alone are limited. As a research chemical, it is handled with standard laboratory safety precautions. The compound is for research use only and not for human therapeutic use. Toxicity profiles are typically evaluated in the context of specific PROTAC molecules during preclinical development. Standard in vitro cytotoxicity assays (e.g., MTT on various cell lines) and in vivo tolerability studies in rodents would be applicable for safety assessment.
|
| References | |
| Additional Infomation |
SLF TFA is a synthetic FKBP ligand widely used as a building block in PROTAC technology. It enables the design of bifunctional molecules that recruit FKBP12 as an E3 ligase adaptor for targeted protein degradation. The compound is available as a trifluoroacetate salt form for improved stability. It is strictly for research purposes and has not been approved for clinical use. SLF TFA is a valuable tool for studying protein homeostasis and developing novel therapeutic strategies.
|
| Molecular Formula |
C32H41F3N2O8
|
|---|---|
| Molecular Weight |
638.671760320663
|
| Exact Mass |
638.281
|
| CAS # |
2378802-47-0
|
| Related CAS # |
SLF;195513-96-3
|
| PubChem CID |
155981980
|
| Appearance |
Light brown to brown solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
885
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(F)(F)(F)C(=O)O.C(N1CCCC[C@H]1C(=O)O[C@@H](C1C=CC=C(N)C=1)CCC1C=CC(OC)=C(OC)C=1)(=O)C(=O)C(C)(C)CC
|
| InChi Key |
HKRBJXCFMLSYKV-KZDWWKKTSA-N
|
| InChi Code |
InChI=1S/C30H40N2O6.C2HF3O2/c1-6-30(2,3)27(33)28(34)32-17-8-7-12-23(32)29(35)38-24(21-10-9-11-22(31)19-21)15-13-20-14-16-25(36-4)26(18-20)37-5;3-2(4,5)1(6)7/h9-11,14,16,18-19,23-24H,6-8,12-13,15,17,31H2,1-5H3;(H,6,7)/t23-,24+;/m0./s1
|
| Chemical Name |
[(1R)-1-(3-aminophenyl)-3-(3,4-dimethoxyphenyl)propyl] (2S)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (156.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (7.83 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5658 mL | 7.8288 mL | 15.6575 mL | |
| 5 mM | 0.3132 mL | 1.5658 mL | 3.1315 mL | |
| 10 mM | 0.1566 mL | 0.7829 mL | 1.5658 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
